StreetAlpha
13F holdings · Q3 2026

Foresite Capital Management IV

West Hollywood, CA · files as Foresite Capital Management IV, LLC
Know the moment Foresite Capital Management IV filesYou follow Foresite Capital Management IV An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1704132

Foresite Capital Management IV reported 6 stocks worth $252M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PHVS (60.1%), CYTK (18.7%) and RLAY (8.9%). Compared with Q2 2026, the fund opened new positions in VCYT.

Latest filing: what Foresite Capital Management IV did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
1 new0 added0 trimmed1 sold outBought about $9.2M · sold about $5.6M
New 1
Added 0

None

Trimmed 0

None

Sold out 1
  • Crinetics Pharmace$5.6M

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$252M−13.1% vs last quarter
Stocks held61 new · 1 sold out
Top 5 weight97.6%very concentrated
Turnover6%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
PHVS
Pharvaris N V
$152M60.1%4.8MNo change8 of 8
2
CYTK
Cytokinetics Inc
$47.1M18.7%715KNo change5 of 8
3
RLAY
Relay Therapeutics Inc
$22.6M8.9%1.3MNo change8 of 8
4
EIKN
Eikon Therapeutics Inc
$15.6M6.2%1.9MNo change3 of 8
5
VCYT
Veracyte Inc
$9.2M3.6%200KNew position1 of 8
6
XENE
Xenon Pharmaceuticals Inc
$6M2.4%160KNo change6 of 8

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
CRINETICS PHARMACEUTICALS IN
$5.6M150K

Reported value

last 8 quarters
$109MQ4 '24
$111MQ1 '25
$124MQ2 '25
$183MQ3 '25
$230MQ4 '25
$237MQ1 '26
$290MQ2 '26
$252MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Foresite Capital Management IV 13F FAQ

What does Foresite Capital Management IV own?

Foresite Capital Management IV reported 6 stocks worth $252M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PHVS (60.1%), CYTK (18.7%) and RLAY (8.9%). The table above lists every position in the filing (the top 10 without an account).

What did Foresite Capital Management IV buy and sell in Q3 2026?

Compared with Q2 2026: 1 new positions, 0 added to, 0 trimmed and 1 sold out. New positions include VCYT.

When will Foresite Capital Management IV file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Foresite Capital Management IV's portfolio worth?

The Q3 2026 filing reports $252M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.